Product
Help
Pricing
About
Jobs
Log in
Get started
Author
Add to collection
Melinda A. L. Day
Observed names:
Melinda A. Day,
Melinda A.L. Day,
Melinda Day
Institution:
Cyteir Therapeutics (United States)
Observed institution:
Cyteir Therapeutics (United States)
OpenAlex ID:
A5083416148
Discovery of KB-0742, a Potent, Selective, Orally Bioavailable Small Molecule Inhibitor of CDK9 for MYC-Dependent Cancers
2023
·
David B. Freeman
, Tamara D. Hopkins
, et al.
·
Journal of Medicinal Chemistry
·
57
PDF
Abstract P2-05-05: RAD51 inhibition using CYT-0851, shows anti-cancer activity in cellular models of breast cancer and acts synergistically with PARP inhibitors
2020
·
Joey L Guy
, Tyler Maclay
, et al.
·
Cancer Research
·
10
Abstract P5-08-05: Preclinical activity of KB-0742, an oral, highly selective, CDK9 inhibitor, in cell lines and in MYC-high expressing, patient-derived models of multiple breast cancer subtypes
2022
·
Douglas C. Saffran
, Melinda A.L. Day
, et al.
·
Cancer Research
·
9
Abstract P228: Preclinical pharmacokinetics and pharmacodynamics of KB-0742, a selective, oral CDK9 inhibitor
2021
·
Melinda A. L. Day
, Douglas C. Saffran
, et al.
·
Molecular Cancer Therapeutics
·
6
Abstract 363: CYT01B, a novel RAD51 inhibitor, acts synergistically with PARP inhibitors
2019
·
Tyler Maclay
, Melinda Day
, et al.
·
Cancer Research
·
6
CYT01B, a Novel RAD51 Inhibitor, Act Synergistically with Both Targeted and Chemotherapeutic Anti-Cancer Agents
2018
·
Tyler Maclay
, Joseph Vacca
, et al.
·
Blood
·
6
Abstract C14: A novel RAD51 inhibitor, CYT-0851, shows anticancer activity in preclinical models of pancreatic cancer
2019
·
Melinda Day
, Jean-Marc Lapierre
, et al.
·
Cancer Research
·
5
Abstract 2564: CDK9 inhibition via KB-0742 is a potential strategy to treat transcriptionally addicted cancers
2022
·
Melinda A. Day
, Douglas C. Saffran
, et al.
·
Cancer Research
·
4
Abstract 2565: CDK9 inhibitor KB-0742 is active in preclinical models of small-cell lung cancer
2022
·
Melinda A. Day
, Douglas C. Saffran
, et al.
·
Cancer Research
·
3
Abstract 1141: CDK9 inhibition is selective for transcriptionally addicted tumors harboring MYC genomic amplifications
2021
·
Melinda A. Day
, Nikolaus D. Obholzer
, et al.
·
Cancer Research
·
3
Preclinical Activity of Selective SYK Inhibitors, Entospletinib and Lanraplenib, Alone or Combined with Targeted Agents in Ex Vivo AML Models with Diverse Mutational Backgrounds
2021
·
Melinda A. L. Day
, Philipp Sergeev
, et al.
·
Blood
·
2
Targeting Homologous Recombination in Lymphoid Malignancies: Evaluation of Four Small Molecule Inhibitors of RAD51
2019
·
Melinda Day
, Tyler Maclay
, et al.
·
Blood
·
1
Ongoing Spontaneous DNA Damage Creates Synthetic Lethality Targeted By Novel RAD51 Inhibitors in Multiple Myeloma
2019
·
Subodh Kumar
, Maria Gkotzamanidou
, et al.
·
Blood
·
1
Abstract 4730: A novel RAD51 inhibitor, CYT01B, shows anti-cancer activity in preclinical models of AID expressing solid tumors
2019
·
Melinda Day
, Tyler Maclay
, et al.
·
Cancer Research
·
1
Abstract 535: Development of a liquid biopsy assay to longitudinally monitor changes in mutations’ allelic frequency in response to treatment with KB-0742
2022
·
Suha Naffar-Abu Amara
, Christina Noe
, et al.
·
Cancer Research
Abstract 2639: KB-0742 is active in preclinical MYC high models of TNBC, ovarian, and DLBCL cancers
2022
·
Melinda A. Day
, Douglas C. Saffran
, et al.
·
Cancer Research
CYT-0853, a Novel RAD51 Inhibitor, Modulates Immunoregulatory B-Lymphocytes
2019
·
Tamar Aprahamian
, ED Keniston
, et al.
·
Blood
Abstract 363: CYT01B, a novel RAD51 inhibitor, acts synergistically with PARP inhibitors
2019
·
Tyler Maclay
, Melinda Day
, et al.
·
Experimental and Molecular Therapeutics
Abstract 4730: A novel RAD51 inhibitor, CYT01B, shows anti-cancer activity in preclinical models of AID expressing solid tumors
2019
·
Melinda Day
, Tyler Maclay
, et al.
·
Experimental and Molecular Therapeutics
Abstract 2566: CYT01B suppresses RAD51 focus formation and induces replication catastrophe following AID induced DNA damage
2019
·
Melinda Day
, Amber Cyr
, et al.
·
Cancer Research
A Novel RAD51 Inhibitor, CYT01B, Shows Anti-Cancer Activity in Preclinical Models of Aid Expressing Lymphomas
2018
·
Muneer G Hasham
, Darryl Patrick
, et al.
·
Blood
Abstract 347: Targeting the AICDA/RAD51 axis: A novel gain-of-function synthetic lethal therapy for the treatment of AICDA-expressing cancers
2018
·
Muneer Hasham
, Kin-hoe Chow
, et al.
·
Cancer Research
Show more works
View as search
Works count:
22
Citation count:
114
H-index:
6
I10-index:
2
Year
Topic
Type